Market news

iRadimed Corp (IRMD) navigates a pivotal transition quarter with robust bookings for its next-generation MRI pump, offset by near-term margin pressure and flat revenue growth.

Moby summary of IRadimed Corporation's Q2 2026 earnings call

iRadimed (NASDAQ:IRMD) reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp. GAAP net income was $5.2 million,

IRadimed (IRMD) reported Q2 non-GAAP earnings Friday of $0.46 per diluted share, compared with $0.49

Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark performed well during a speculative period for micro caps. Over the […]